Mode
Text Size
Log in / Sign up

Bowel Dose-Volume Predictors of GI Toxicity in Postoperative Radiotherapy for Cervical Cancer

Bowel Dose-Volume Predictors of GI Toxicity in Postoperative Radiotherapy for Cervical Cancer
Photo by Dmytro Vynohradov / Unsplash
Key Takeaway
Consider using bowel V30Gy and V40Gy as predictors for GI toxicity; IMRT may reduce risk, but models need validation.

The PARCER trial was a multicenter phase III RCT involving 283 patients with cervical cancer undergoing postoperative radiotherapy with or without chemotherapy. The study compared intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3DCRT) techniques. Median follow-up was 43 months.

Main results showed that bowel V30Gy and V40Gy were associated with acute ≥G2 diarrhea, late ≥G2 diarrhea, and persistent GI toxicity. IMRT reduced the risk of late ≥G2 diarrhea and persistent GI toxicity. However, radical hysterectomy with bilateral lymphadenectomy increased the risk of persistent GI toxicity.

Model performance was modest, with AUC values of 0.761 for late ≥G2 diarrhea and 0.588 for persistent GI toxicity. No absolute risk reductions or numbers needed to treat were reported. Safety assessment focused on GI toxicity graded by CTCAEv3.0; serious adverse events and discontinuations were not reported.

Limitations include modest model discrimination and the need for external validation. The study reports associations, not causation. These NTCP models may help individualize radiotherapy planning to reduce GI toxicity, but further research is needed.

Study Details

Study typeRct
EvidenceLevel 2
PublishedMay 2026
View Original Abstract ↓
BACKGROUND AND PURPOSE: Gastrointestinal (GI) side effects are common after radiotherapy for gynecological cancers. Normal tissue complication probability (NTCP) models providing individual risk estimates for GI adverse events in gynecological cancers are not yet available. The aim of this study was to develop NTCP models for GI toxicity after postoperative (chemo)radiotherapy for cervical cancer. MATERIALS AND METHODS: Data from the phase-III PARCER trial (NCT01279135) was used. Tested variables included patient- and treatment-related characteristics and dosimetric parameters of small, large, and total individual bowel loops, and bowel bag as peritoneal space. NTCP endpoints included acute and late ≥G2 diarrhea and GI toxicity (CTCAEv3.0) and late persistent GI toxicity defined with the Cumulative-Month and Severity Score (C-MOSES). Logistic or Cox regression were used for multivariable models, selecting variables with Least Absolute Shrinkage and Selection Operator. Internal model performance was evaluated with area-under-the-curve (AUC) or C-index. RESULTS: The median follow-up of the 283 included patients was 43 months. Volumes of the bowel receiving 30 Gy (V30Gy) and 40 Gy (V40Gy) were associated with acute and late ≥G2 diarrhea and persistent GI toxicity. IMRT reduced risk of late ≥G2 and persistent GI toxicity, whereas radical hysterectomy with bilateral lymphadenectomy increased it. AUC/C-indices ranged from 0.588 (persistent GI toxicity) to 0.761 (late ≥ G2 diarrhea). CONCLUSION: NTCP models for acute and late diarrhea and persistent GI toxicity after postoperative radiotherapy for cervical cancer included bowel V30Gy and V40Gy. Furthermore, 3DCRT and more extensive surgery increased risks. Further studies should explore additional variables to improve model performance, reach consensus on bowel delineation methods, and validate models externally.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.